Aim: To evaluate the diagnostic value of serum cancer antigen (CA)125, CA19-9 and CA15-3 concentrations in endometriosis. Methods: Case-control studies evaluating CA125, CA19-9 and CA15-3 and endometriosis, published between January 2000 and November 2014 were retrieved from PubMed Õ and Google Scholar. Standardized mean differences (SMD) and 95% confidence intervals (CI) were calculated. Subgroup analyses were carried out by ethnicity and disease stage (early, stage I/II; advanced, stage III/IV). Results: The analysis included 12 case-control studies (963 cases, 855 controls). CA125 was associated with endometriosis in the overall population (SMD 0.82, 95% CI 0.72, 0.92), Caucasian subgroup (SMD 1.08, 95% CI 0.96, 1.19), and early (SMD 1.20, 95% CI 0.93, 1.48) or advanced disease (SMD 1.29, 95% CI 1.04, 1.55). CA19-9 was associated with endometriosis in the overall population (SMD 0.48, 95% CI 0.24, 0.72), Caucasian subgroup (SMD 0.31, 95% CI 0.07, 0.55), Asian subgroup (SMD 9.65, 95% CI 7.88, 11.42) and advanced disease (SMD 0.60, 95% CI 0.34, 0.87). CA15-3 was significantly associated with advanced disease (SMD 0.47, 95% CI 0.09, 0.84). Conclusions: Serum CA125 and CA19-9 may represent useful biomarkers for the noninvasive diagnosis of endometriosis.
Introduction
Endometriosis is a benign gynaecological disease that occurs in up to 10% of women of reproductive age (16-50 years old). 1 It can cause dyspareunia, dysmenorrhoea, menstrual irregularities, low back pain and infertility. 2, 3 Although the most accurate diagnostic method is histological examination of laparascopically excised lesions, less-invasive auxiliary tests have been developed, including the use of biochemical markers. 4 Elevated serum concentrations of cancer antigen [CA] 125, CA19-9, and CA15-3 are observed in some carcinomas, [5] [6] [7] and are considered oncofetal antigens, or serum tumour markers. Serum CA125 concentration was first used in the diagnosis of endometriosis in 1983, 8 followed by several other biomarkers including CA19-9, CA15-3, copeptin, interleukin (IL)-6 and IL-8. [9] [10] [11] [12] [13] Published data regarding these biomarkers are inconsistent due to study limitations including small sample size, use of outdated assay techniques, and quantification of a limited number of biomarkers. The diagnostic value of serum CA125, CA19-9 and CA15-3 concentration in endometriosis therefore remains unclear. The aim of the present meta-analysis was to evaluate the association between serum CA125, CA19-9 and CA15-3 and endometriosis, by analysing data from studies using current assay techniques.
Materials and methods

Search strategy
A systematic search of PubMed Õ and Google Scholar was performed to identify studies published between January 2000 and November 2014 using the keywords ''CA125'', ''CA19'', ''CA15'' and ''endometriosis''. Inclusion criteria were: (i) casecontrol studies published in peer reviewed journals; (ii) full text available; (iii) studies focusing on the relationship between serum CA125, CA19-9 or CA15-3 concentration and endometriosis; (iv) raw data available, including numbers of cases and controls and mean AE SD biomarker concentrations. All studies related to CA125, CA1-9 and CA15-3 were included, with no restriction on the number of biomarkers investigated in each study.
Data extraction
Data were reviewed and extracted independently by two reviewers (Y.M. and C.L.). Data retrieved included name of first author, year of publication, country of study, ethnicity, mean AE SD biomarker concentration, and numbers of cases and controls. All disagreements were resolved by consensus, with unresolved issues referred to a third author. In the case of duplicate articles, only the most comprehensive and/or the most recently published were included.
Statistical analyses
The mean differences of each included study were expressed as the standardized mean difference (SMD) and 95% confidence intervals (CI), with statistical significance defined as occurring when 95% CI did not include 0.0. Independent analyses were performed for each biomarker (CA125, CA19-9 and CA15-3). Subgroup analyses were carried out by ethnicity (Caucasian or Asian), clinical stage (early [stage I/II] or advanced [stage III/IV]). The I 2 statistic was calculated to evaluate the heterogeneity among trials. The Mantel-Haenszel fixed-effects model was applied in cases of low heterogeneity (I 2 < 50), and the random-effects model was Table 1 . Characteristics of studies included in a meta-analysis of the diagnostic value of serum cancer antigen (CA) 125, CA19-9 and CA15-3 concentration in endometriosis.
Author, year
Country Ethnicity 
Results
The search strategy identified 12 qualifying studies (963 cases and 855 controls; Figure 1 , Table 1 ). 9, 11, 12, [14] [15] [16] [17] [18] [19] [20] [21] [22] All studies evaluated CA125, four studied CA19-9, 9, 11, 12, 20 and two CA15-3. 9,12 A total of nine studies included Caucasian populations, 9, 11, 12, 14, [16] [17] [18] 21, 22 and three included Asian populations. 15, 19, 20 There was statistically significant heterogeneity (I 2 > 90%) in all CA125 datasets (overall, Caucasian and Asian), therefore a random-effects model was used. Findings of the meta-analysis are given in Table 2 , with forest plots shown in Figure 2 . There were significant associations between serum CA125 concentration and endometriosis in the overall population (SMD 0.82, 95% CI 0.72, 0.92; Figure 2 [a]) and the Caucasian subgroup (SMD 1.08, 95% CI 0.96, 1.19; Figure 2 [b]) but not in the Asian subgroup (SMD À 0.06, 95% CI À 0.27, 0.15; Figure 2 [c]). There was no evidence of publication bias in the overall or Caucasian groups (Table 2; Figure 3 ). It was not possible to determine publication bias in the Asian subgroup due to the small sample size (data not shown).
There was statistically significant heterogeneity (I 2 > 60%) in all CA19-9 and CA15-3 datasets, therefore a random-effects model was used. Results of the meta-analysis are shown in Table 2 , with forest plots in Figure 4 . CA19-9 was significantly associated with endometriosis in the overall population (SMD 0.48, 95% CI 0.24, 0.72; Figure 4 [a]), Caucasian subgroup (SMD 0.31, 95% CI 0.07, 0.55; Figure 4 [b]) and the Asian subgroup (SMD 9.65, 95% CI 7.88, 11.42 Figure 4 [c]). Tests found no evidence for publication bias in the overall population, but were not performed in Caucasian and Asian subgroups due to the Table 2 . Findings of a meta-analysis of the diagnostic value of serum cancer antigen (CA) 125, CA19-9 and CA15-3 concentration in endometriosis, in the overall population and Caucasian and Asian subgroups.
Analysis Model Analysis Method
Heterogeneity SMD (95% CI) small sample size. There was no significant association between CA15-3 and endometriosis in the overall population (SMD 0.26, 95% CI À 0.03, 0.55 (Figure 4[d] ). Neither ethnicity based subgroup analyses nor assessments of publication bias were conducted for CA15-3 due to small sample size. Data regarding the associations between biomarker concentration and endometriosis stage are given in Table 3 , with forest plots shown in Figure 5 . There was significant heterogeneity for stage III/IV in the CA125 and CA19-9 datasets and stage I/II in the CA15-3 dataset. Meta-analysis indicated that CA125 was associated with both early (I/II; SMD 1.20, 95% CI 0.93, 1.48; Figure  5 [a]) and advanced stage disease (III/IV; SMD 1.29, 95% CI 1.04, 1.55; Figure 5 [b]). Serum CA19-9 was significantly associated with stage III/IV disease (SMD 0.60, 95% CI 0.34, 0.87; Figure 5 [d]) but not with stage I/II disease ( Figure 5[c] ). Similarly, CA15-3 (SMD 0.47, 95% CI 0.09, 0.84; Figure 5 [f]) was significantly associated with stage III/IV disease but not with stage I/II disease ( Figure 5[e] ).
Discussion
The diagnosis of endometriosis can be delayed up to 8.5 years from the onset of symptoms. [23] [24] [25] Although laparoscopy is the gold-standard diagnostic method, $66% of women who undergo laparoscopy are found to be free of the disease. Taken together with the potential risks and cost associated with laparoscopy, 26 the development of a noninvasive diagnostic method would have a huge impact on patients' health-related quality-of-life and reduce the number of unnecessary interventions. 27 The current meta-analysis found that the serum CA125 concentration was associated with endometriosis in Caucasian, Asian and overall populations, and with both early and advanced stage disease. This elevated serum CA125 might be due to the induction of inflammatory reactions that alter endothelial permeability, allowing CA125 to reach the circulation, or the higher CA125 concentration in ectopic rather than entopic endometrium. 28 Our meta-analysis confirmed the clinical value of CA125 as an auxiliary biological marker in endometriosis diagnosis.
Statistically significant associations between CA19-9 and endometriosis were observed in Caucasian, Asian and overall populations in the present analysis, in accordance with the findings of others. 29 In a finding consistent with others, 30, 31 our results showed that CA19-9 was significantly associated with advanced stage (stage III and IV) endometriosis. CA19-9 may therefore be useful in the diagnosis of later-stage disease.
The present meta-analysis found that CA15-3 is not useful for the general diagnosis of endometriosis, but that it may be a valid biomarker of advanced disease. Our finding is in contrast to other research, 9 which reported no significant increase in serum CA15-3 levels in patients with endometriosis.
In conclusion, endometriosis is significantly associated with elevated serum CA125 and CA19-9 concentrations, and CA19-9 is increased further in the more advanced stages of disease. Serum CA125 and CA19-9 may represent useful biomarkers for the noninvasive diagnosis of endometriosis.
